Your browser is no longer supported. Please, upgrade your browser.
Settings
PRPO Precipio, Inc. daily Stock Chart
PRPO [NASD]
Precipio, Inc.
Index- P/E- EPS (ttm)-3.22 Insider Own11.48% Shs Outstand23.05M Perf Week10.53%
Market Cap7.26M Forward P/E- EPS next Y-1.94 Insider Trans- Shs Float20.53M Perf Month0.77%
Income-31.60M PEG- EPS next Q0.57 Inst Own5.40% Short Float6.97% Perf Quarter-27.08%
Sales2.70M P/S2.69 EPS this Y39.50% Inst Trans-33.46% Short Ratio2.16 Perf Half Y-21.43%
Book/sh0.59 P/B0.53 EPS next Y16.70% ROA-114.30% Target Price20.00 Perf Year-76.67%
Cash/sh0.00 P/C72.61 EPS next 5Y20.00% ROE-221.10% 52W Range0.25 - 1.75 Perf YTD-73.75%
Dividend- P/FCF- EPS past 5Y31.70% ROI-99.90% 52W High-82.86% Beta0.45
Dividend %- Quick Ratio0.10 Sales past 5Y-44.10% Gross Margin16.40% 52W Low19.96% ATR0.03
Employees19 Current Ratio0.10 Sales Q/Q166.70% Oper. Margin- RSI (14)48.46 Volatility8.56% 10.42%
OptionableNo Debt/Eq0.30 EPS Q/Q99.00% Profit Margin- Rel Volume1.26 Prev Close0.31
ShortableYes LT Debt/Eq0.23 Earnings- Payout- Avg Volume661.87K Price0.30
Recom1.00 SMA203.31% SMA50-13.53% SMA200-35.32% Volume627,030 Change-4.79%
Nov-14-18 09:30AM  4 Healthcare Stocks To Watch On Wednesday ACCESSWIRE
09:15AM  Webinar to Highlight Technology Underlying Precipios ICE COLD-PCR on November 20, 2018 GlobeNewswire
Nov-01-18 09:15AM  Precipio and PerkinElmer Collaborate to Provide Solutions for Liquid Biopsy Testing Workflows GlobeNewswire +7.41%
Oct-23-18 09:15AM  Precipio Expands ICE COLD-PCR Menu for Breast, Colon and Endometrial Cancers GlobeNewswire
Oct-18-18 07:36AM  Innovation Behind Precipios ICE-COLD PCR Platform Spotlighted in Media GlobeNewswire
Oct-16-18 07:47AM  Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues GlobeNewswire +5.57%
Oct-03-18 07:47AM  Precipio Launches HemeScreen, a Disruptive, Proprietary Molecular Test for Hematologic Cancers GlobeNewswire
Sep-27-18 07:37AM  Precipio Granted 180 Day NASDAQ Extension to Regain Compliance GlobeNewswire
Sep-21-18 09:18AM  Precipio Enters into Exchange Agreement to Restructure Remaining Legacy Accounts Payable for approximately 20% of Original ~$5M GlobeNewswire
Sep-20-18 07:37AM  Precipio Expands ICE-COLD PCR Lung Cancer Mutation Detection Offering GlobeNewswire
Aug-23-18 07:00AM  Precipio, Inc. to Host Earnings Call ACCESSWIRE -8.42%
Aug-22-18 09:45PM  Precipio Reminds Investors of Conference Call with Management for Corporate Update and Second Quarter Results GlobeNewswire +7.91%
Aug-17-18 07:37AM  Precipio Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-18 07:37AM  Precipio Appoints New Board Member to Replace Departing Director GlobeNewswire
Jul-19-18 08:10AM  Todays Research Reports on Stocks to Watch: Texas Instruments and Precipio ACCESSWIRE -12.08%
Jul-18-18 07:37AM  Precipio Announces 213% Year-over-Year Revenue Growth in Preliminary Q2-2018 Results GlobeNewswire +29.14%
Jun-26-18 08:00AM  Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution GlobeNewswire
07:05AM  Initiating Free Research Reports on Quest Diagnostics and Three Other Medical Research Equities ACCESSWIRE
Jun-19-18 07:38AM  Precipio Updates Commercial Pipeline for its ICE-COLD PCR Liquid Biopsy Technology GlobeNewswire -6.44%
Jun-15-18 08:11PM  Precipio Inc. Announces Adjournment of Annual Meeting of Shareholders GlobeNewswire
Jun-14-18 12:19PM  Precipio Reminds Shareholders to Vote Before the Annual General Meeting on June 15, 2018 GlobeNewswire
Jun-12-18 08:00AM  Precipio Reminds Shareholders to Vote Before the Annual General Meeting on June 15, 2018 GlobeNewswire
Jun-06-18 07:38AM  Precipio Strengthens Patent Portfolio with Expanded Kit Claims for its Liquid Biopsy Enabling DNA Mutation Enrichment Technology GlobeNewswire
May-24-18 12:43PM  Who Owns Most Of Precipio Inc (NASDAQ:PRPO)? Simply Wall St. +7.60%
07:38AM  Precipio Launches Liquid Biopsy DNA Enrichment Sales in Europe with First Order GlobeNewswire
May-22-18 07:37AM  Potential Sequential Revenue Run-Rate Growth of 30% over Q1, based on Preliminary April Results GlobeNewswire +16.61%
07:10AM  Complimentary Technical Snapshots on Thermo Fisher Scientific and Three More Medical Research Stocks ACCESSWIRE
May-17-18 07:38AM  Precipio Launches ICE COLD-PCR Liquid Biopsy Kit for Pancreatic Cancer GlobeNewswire +6.96%
May-15-18 08:00AM  Todays Research Reports on Stocks to Watch: Precipio and Teva Pharmaceutical ACCESSWIRE -11.20%
May-14-18 07:37AM  Precipio Announces Preliminary Q1 2018 Year-over-Year Revenue Increase of 286% GlobeNewswire +25.18%
Apr-26-18 07:38AM  Precipio Announces Participation Details for Upcoming Shareholder Conference Call GlobeNewswire
Apr-23-18 07:37AM  Precipio Completes a $3M Convertible Debt Facility GlobeNewswire
Apr-18-18 07:38AM  Precipio in Strategic Partnership Discussions for Proprietary Cytogenetics Media IV-Cell GlobeNewswire +5.72%
Apr-17-18 07:37AM  Precipio Releases its 2017 10-K, Files a form S-1, and hosts Fourth Quarter and Full Year Update Call GlobeNewswire
Apr-11-18 07:37AM  Precipio Launches ICE COLD-PCR Research Access Program for Cancer Centers GlobeNewswire +10.20%
Apr-10-18 12:23PM  Precipio Inc (NASDAQ:PRPO): Time For A Financial Health Check Simply Wall St.
Apr-03-18 07:38AM  Important JAMA Article Underscores Superiority of Precipios Liquid Biopsy Core Technology GlobeNewswire -8.92%
Mar-28-18 07:37AM  Precipio Files Patent for Non-Invasive Cell Capture Device For Gynecological Cancer Detection GlobeNewswire +5.78%
Mar-26-18 07:38AM  Precipio Enters India Liquid Biopsy Market with Adoption by Leading Laboratory GlobeNewswire
Mar-22-18 07:37AM  Precipio Restructures Capitalization Table GlobeNewswire -9.84%
Mar-20-18 07:37AM  Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform GlobeNewswire +88.82%
Mar-13-18 08:38AM  Precipio Settles Lawsuit with Crede Capital GlobeNewswire +21.02%
Feb-22-18 08:39AM  Key Measure of Precipios Pathology Sales Growth 4X Prior Quarter GlobeNewswire +7.50%
Feb-15-18 08:38AM  Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance GlobeNewswire -6.49%
Feb-09-18 09:00AM  Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter GlobeNewswire -14.43%
Feb-06-18 08:37AM  Precipio Enters Japanese Liquid Biopsy Market with First Hospital Sale GlobeNewswire
Jan-22-18 08:27AM  Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania GlobeNewswire
Jan-16-18 08:27AM  Precipio Appoints New Sales VP to Manage Diagnostics Sales Expansion GlobeNewswire -8.46%
Jan-10-18 08:27AM  Yale Study Demonstrates Four-Fold Superiority of Academic Level Diagnostic Accuracy GlobeNewswire
Dec-20-17 08:00AM  Precipio Launches Its Second New ICE-COLD PCR Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies On Sanger Sequencing Platforms GlobeNewswire +6.49%
Dec-15-17 09:00AM  OrthoPediatrics Corp. Appoints Samuel D. Riccitelli to its Board of Directors GlobeNewswire -9.17%
Dec-14-17 08:00AM  Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media GlobeNewswire +9.09%
Dec-01-17 07:57AM  Precipio, Inc. :PRPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017 Capital Cube
Nov-21-17 07:00AM  Precipio, Inc. to Host Earnings Call ACCESSWIRE
Nov-20-17 04:05PM  Precipio Announces Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire -5.15%
Nov-16-17 04:15PM  Precipio To Announce Third Quarter 2017 Financial Results and Provide a Company Update on Monday, November 20, 2017 at 4:05pm Eastern Time GlobeNewswire +7.94%
Nov-14-17 04:15PM  Precipio Appoints Samuel D. Riccitelli as Chairman of the Board of Directors and Elects David Cohen as Director GlobeNewswire
Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.